



# Tofacitinib-induced remission simultaneously in arthritis and vitiligo

Morton Scheinberg<sup>1</sup> , Sineida Berbert Ferreira<sup>2</sup> , Durval do Carmo Barros Santos<sup>3</sup> 

Tofacitinib is a Janus kinase inhibitor that was approved for the treatment of rheumatoid arthritis. Other indications pending clinical trials and observational reports such as alopecia areata vitiligo and atopic dermatitis are under evaluation (1-4). For the past four years, we treated a 30-year-old female with pain and swelling of her hands and knees, her synovial fluid analysis showed inflammatory fluid, and the diagnosis of sero negative rheumatoid arthritis was performed. In an attempt to improve arthritis, an orthopedic procedure was performed and synovial biopsy obtained showed chronic non-specific synovial inflammation. The patient also complained from vitiligo that antecedes arthritis for a few years. She started Tofacitinib 5 mg twice a day and marked improvement was observed on both diseases with significant reduction in pain swelling and almost no complain of arthritis; her vitiligo lesions improved as well, becoming almost fully repigmented after 4 months of continuous therapy. Figures 1 and 2 show outcome of arthritis and skin disease. Consent information was provided by the patient.



**Figure 1. a, b.** The disappearance of synovial thickening is appreciated on magnetic resonance imaging (a). Synovial thickening disappeared after therapy (b).



**Figure 2. a, b.** Resolution of hypopigmented lesions before (a) and after therapies (b).

**Cite this article as:** Scheinberg M, Ferreira SB, Santos DCB. Tofacitinib-induced remission simultaneously in arthritis and vitiligo. Eur J Rheumatol 2021; 8(1): 55-6.

<sup>1</sup> Section of Rheumatology, Orthopedic Division Hospital Israelita Albert Einstein and Center of Autoimmune Diseases Hospital BP Mirante, São Paulo, Brazil

<sup>2</sup> Clinica Dermatologica, Maringá, Brazil

<sup>3</sup> Musculoskeletal Radiology Division, Imaging Department, Hospital Israelita Albert Einstein, São Paulo, Brazil

**Address for Correspondence:**

Morton Scheinberg; Section of Rheumatology, Orthopedic Division Hospital Israelita Albert Einstein and Center of Autoimmune Diseases Hospital BP Mirante, São Paulo, Brazil

E-mail: mortonascheinberg@gmail.com

Submitted: January 16, 2020

Accepted: March 24, 2020

Available Online Date: September 08, 2020

Copyright©Author(s) - Available online at [www.eurjrheumatol.org](http://www.eurjrheumatol.org).

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



**Informed Consent:** Informed consent was obtained from the patient.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - M.S.; Writing Manuscript - M.S., S.B.F., D.C.B.; Critical Review - S.B.F., D.C.B.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors - for the treatment of autoimmune and inflammatory diseases. *Autoimmun Rev* 2019; 18: 102390. [\[Crossref\]](#)
2. Scheinberg M, de Lucena Couto Ocáa RA, Cruz BA, Ferreira SB. Brazilian experience on the treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A case series. *Rheumatol Ther* 2017; 4: 503-8. [\[Crossref\]](#)
3. Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy. *JAMA Dermatol* 2015; 151: 1110-2. [\[Crossref\]](#)
4. Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. *J Am Acad Dermatol* 2018; 78: S53-62. [\[Crossref\]](#)